Search Result

Results for "

heterodimers

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (5) Bacterial (1) Biochemical Assay Reagents (2) Bombesin Receptor (1) c-Myc (2) COX (2) Cryptochrome (1) DNA-PK (3) Dopamine Receptor (1) EGFR (2) Endogenous Metabolite (6) Fungal (1) GABA Receptor (1) Integrin (1) Isotope-Labeled Compounds (1) JAK (1) Lipoxygenase (2) MEK (1) Microtubule/Tubulin (2) Molecular Glues (1) NF-κB (2) Nuclear Hormone Receptor 4A/NR4A (1) Opioid Receptor (1) Potassium Channel (5) PSMA (1) Raf (1) RAR/RXR (4) SHP2 (1) Toll-like Receptor (TLR) (2) VD/VDR (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (3) Infection (2) Inflammation/Immunology (8) Metabolic Disease (7) Neurological Disease (11)
Oligonucleotides:	Nucleosides and their Analogs (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99676

Izalontamab SI-B001	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-Y1666

2,2′-Dipyridyl disulfide	Biochemical Assay Reagents	Others
2,2′-Dipyridyl disulfide is a useful reagent for the determination of sulfhydryl groups. 2,2′-Dipyridyl disulfide is a common reagent in peptide chemistry, often used in oxidation–reduction condensations to form peptide bonds or in coupling reactions to form disulfide-linked heterodimers .

HY-P3229

SN52 2 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-125978

JY-3-094	c-Myc	Cancer
JY-3-094 is a Myc inhibitor that inhibits Myc-Max heterodimer formation (IC₅₀: 33 μM) .

HY-163829

TLR2 agonist 1	Toll-like Receptor (TLR) NF-κB	Cancer
TLR2 agonist 1 (Compound R-7d) is an agonist for human toll-like receptor 2 (TLR 2) with an EC₅₀ of 116 pM. TLR2 agonist 1 enhances NF-κB promoter activation through TLR2/TLR1 heterodimers .

HY-149536

TWIK-1/TREK-1-IN-1	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .

HY-P10405

TAT-D1 peptide	Dopamine Receptor	Neurological Disease
TAT-D1 peptide is a selective D1-D2 heterogeneous antagonist. TAT-D1 peptide destroys the heterodimer of the D1-D2 receptor by interacting with the specific domain of the D2 receptor through its unique amino acid sequence, in particular the two glutamate residues at the C terminal of the D1 receptor. TAT-D1 peptide can be used to study the role of D1-D2 receptor heterodimers in the regulation of depressive and anxiety-like behaviors .

HY-142943

DNA-PK-IN-1	DNA-PK	Cancer
DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021136463A1, compound 1) .

HY-142944

DNA-PK-IN-2	DNA-PK	Cancer
DNA-PK-IN-2 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2021136462A1, compound 1) .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-110333

BMS-599626 dihydrochloride	EGFR	Cancer
BMS-599626 dihydrochloride is a small molecule pan-HER (human epidermal growth factor receptor) kinase inhibitor. BMS-599626 dihydrochloride primarily targets HER1 (IC₅₀=20 nmol/L) and HER2 (IC₅₀=30 nmol/L) kinase activity in the HER family. BMS-599626 inhibits the kinase activity of HER1 and HER2 by competing with their ATP-binding sites, and can inhibit the downstream signaling pathway by blocking the heterodimer formation of HER1 and HER2. BMS-599626 dihydrochloride can be used to study the antitumor effects of multiple HER1 or HER2 overexpressed tumor models .

HY-122683

sAJM589 1 Publications Verification	c-Myc	Cancer
sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC₅₀ of 1.8 μM .

HY-P1275

Tertiapin-Q 2 Publications Verification	Potassium Channel	Cardiovascular Disease
Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir_1.1).

HY-115672

KS15 2 Publications Verification	Cryptochrome	Cancer
KS15 is an inhibitor of the interactions between cryptochromes (CRYs: CRY1 and CRY2) and the CLOCK:BMAL1 heterodimer. KS15 impairs the feedback actions of CRYs on E-box-dependent transcription (EC₅₀=4.9 μM) by CLOCK:BMAL1 heterodimer, an indispensable transcriptional regulator of the mammalian circadian clock. Anti-proliferative activity .

HY-17029

Epothilone B 5 Publications Verification EPO 906; Patupilone	Microtubule/Tubulin Fungal Apoptosis Antibiotic Bacterial	Infection Cancer
Epothilone B is a microtubule stabilizer with a K_i of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.

HY-112374

NPAS3-IN-1	Others	Neurological Disease
NPAS3-IN-1 is a potent inhibitor of NPAS3-ARNT heterodimerization and regulates NPAS3 transcription by disrupting the heterodimerization of NPAS3 with ARNT at the cellular level .

HY-120875

HX600	RAR/RXR	Neurological Disease
HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity .

HY-168633

PSMA/GRPR ligand 1	Bombesin Receptor PSMA	Cancer
PSMA/GRPR ligand 1 (compound 3 ) is a bispecific PSMA/GRPR ligand that shows dual targeting for PSMA(+) and GRPR(+) tumors .

HY-121896

DSHN	SHP2	Cancer
DSHN is a potent *small heterodimer* partner (SHP)** activator. DSHN inhibits Ccl2 expression and secretion by inhibiting p65 activation of Ccl2 promoter activity. DSHN can be used in research of cancer .

HY-104006

CYM51010	Opioid Receptor	Neurological Disease
CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC₅₀ of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .

HY-108523

LG100754 UVI 2112	RAR/RXR	Metabolic Disease
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .

HY-19528

SAH Maximum Cited Publications 8 Publications Verification SAH (S-Adenosylhomocysteine)	Endogenous Metabolite	Metabolic Disease
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-149538

TWIK-1/TREK-1-IN-3	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .

HY-B0551S

Doxapram-d8	Potassium Channel Isotope-Labeled Compounds	Neurological Disease
Doxapram-d₈ is deuterated labeled Doxapram (HY-B0551). Doxapram inhibits TASK-1, TASK-3 and TASK-1/TASK-3 heterodimer channels with EC50s of 410 nM, 37 μM and 9 μM, respectively.

HY-122727

STL127705 4 Publications Verification	DNA-PK Apoptosis	Cancer
STL127705 (Compound L) is a potent *Ku 70/80 heterodimer* protein inhibitor with an IC₅₀ of 3.5 μM. STL127705 interferes the binding of Ku70/80 to DNA and by inhibits the activation of the DNA-PKCS kinase. STL127705 shows antiproliferative and anticancer activity. STL127705 induces apoptosis** .

HY-19528S

SAH-d4 SAH (S-Adenosylhomocysteine)-d₄	Endogenous Metabolite	Metabolic Disease
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].

HY-19528S1

SAH-13C5 SAH (S-Adenosylhomocysteine)-¹³C₅	Endogenous Metabolite	Metabolic Disease
SAH- ¹³C₅ is the ¹³C-labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].

HY-E70080

Vaccinia virus capping enzyme	Biochemical Assay Reagents	Others
Vaccinia virus capping enzyme is a transcription initiation factor. Vaccinia virus capping enzyme is a heterodimer of D1 (844 aa) and D12 (287 aa) polypeptides that executes all three steps in m7GpppRNA synthesis. Vaccinia virus capping enzyme has been used widely as a reagent for capping and cap-labeling RNAs in vitro .

HY-19528R

SAH (Standard)	Endogenous Metabolite	Metabolic Disease
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .

HY-19528S2

SAH-13C10	Endogenous Metabolite	Metabolic Disease
SAH- ¹³C₁₀ is the ¹³C labeled SAH[1]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[2]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[3].

HY-155160

COX-2/15-LOX-IN-3	Lipoxygenase COX	Inflammation/Immunology
COX-2/15-LOX-IN-3 (compound 5k) is a dual inhibitor of COX-2/15-LOX with IC₅₀s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-3 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS, and NO), with specific anti-inflammatory activity .

HY-155161

COX-2/15-LOX-IN-4	Lipoxygenase COX	Inflammation/Immunology
COX-2/15-LOX-IN-4 (compound 5i) is a dual inhibitor of COX-2/15-LOX with IC₅₀s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-4 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS) with specific anti-inflammatory activity .

HY-150511

3-(3-Phenoxybenzyl)amino-β-carboline	Microtubule/Tubulin Apoptosis	Cancer
3-(3-Phenoxybenzyl)amino-β-carboline is a potent tubulin inhibitor. 3-(3-Phenoxybenzyl)amino-β-carboline promotes selective degradation of αβ-tubulin heterodimers. 3-(3-Phenoxybenzyl)amino-β-carboline induces G2/M phase cell cycle arrest and apoptosis. 3-(3-Phenoxybenzyl)amino-β-carboline exhibits anticancer activity .

HY-117182

LG190178	Apoptosis VD/VDR RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .

HY-100813

Saclofen 3 Publications Verification	GABA Receptor	Neurological Disease Inflammation/Immunology
Saclofen is an orally available competitive GABA_B receptor antagonist with an IC₅₀ of 7.8 μM, but it has a weaker antagonistic effect on GABA_B1b and GABA_B2 heterodimer recombinant receptors. Saclofen can inhibit the binding of baclofen (HY-B007) to rat cerebellar membranes and block the phase shifts in circadian rhythms caused by baclofen. Saclofen has also shown anti-inflammatory and analgesic effects in rats .

HY-158115

NST-628	Molecular Glues Raf MEK	Cancer
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .

HY-149537

TWIK-1/TREK-1-IN-2	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-2 (Compound 2g) is a TWIK-1/TREK-1 inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant .

HY-110353

CU-T12-9 5 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
CU-T12-9 is a specific TLR1/2 agonist with EC₅₀ of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS .

HY-163801

Nurr1 agonist 9	Nuclear Hormone Receptor 4A/NR4A	Neurological Disease
Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC₅₀ of 0.090 µM and a K_d of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC₅₀=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC₅₀=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable .

HY-122566

SMU127 ZINC666243	Others	Cancer
SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer. It induces NF-κB signaling in cells expressing human TLR2 (EC₅₀=0.55 μM) but not cells expressing human TLR3, -4, -5, -7, or -8 when used at concentrations ranging from 0.1 to 100 μM. SMU127 induces the production of TNF-α in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 0.01 to 1 μM. In vivo, SMU127 (0.1 mg/animal) reduces tumor volume in a 4T1 murine mammary carcinoma model.

HY-15128

9-cis-Retinoic acid 1 Publications Verification Alitretinoin	RAR/RXR Apoptosis Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities .

HY-150096

Zasocitinib NDI-034858; TAK-279	JAK	Inflammation/Immunology
Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant K_d of <200 pM .

Cat. No.	Product Name	Target	Research Area

HY-P3229

SN52 2 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-P1275

Tertiapin-Q 2 Publications Verification	Potassium Channel	Cardiovascular Disease
Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir_1.1).

HY-P1949A

Cyclic MKEY TFA	Peptides	Cardiovascular Disease Cancer
Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice .

HY-P10405

TAT-D1 peptide	Dopamine Receptor	Neurological Disease
TAT-D1 peptide is a selective D1-D2 heterogeneous antagonist. TAT-D1 peptide destroys the heterodimer of the D1-D2 receptor by interacting with the specific domain of the D2 receptor through its unique amino acid sequence, in particular the two glutamate residues at the C terminal of the D1 receptor. TAT-D1 peptide can be used to study the role of D1-D2 receptor heterodimers in the regulation of depressive and anxiety-like behaviors .

HY-P1949

Cyclic MKEY	Peptides	Cardiovascular Disease Cancer
Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice .

Cat. No.	Product Name	Target	Research Area

HY-P99676

Izalontamab SI-B001	EGFR	Cancer
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .

HY-P990244

*Anti-Rat FcRn heavy chain heterodimers* Antibody (2G3)**	Inhibitory Antibodies	Others
Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is a mouse-derived IgG1 type antibody inhibitor, targeting to rat FcRn heavy chain heterodimers.

HY-P990818

*Anti-Rat FcRn heavy chain heterodimers* Antibody (1G3)**	Inhibitory Antibodies	Others
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is a kind of mouse IgG1 in vivo mouse antibody, targeting to FcRn heavy chain heterodimers. The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

Cat. No.	Product Name	Chemical Structure

HY-19528S

SAH-d4
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].

HY-19528S2

SAH-13C10
SAH- ¹³C₁₀ is the ¹³C labeled SAH[1]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[2]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[3].

HY-B0551S

Doxapram-d8
Doxapram-d₈ is deuterated labeled Doxapram (HY-B0551). Doxapram inhibits TASK-1, TASK-3 and TASK-1/TASK-3 heterodimer channels with EC50s of 410 nM, 37 μM and 9 μM, respectively.

HY-19528S1

SAH-13C5
SAH- ¹³C₅ is the ¹³C-labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].

Cat. No.	Product Name		Classification

HY-19528

SAH 5+ Cited Publications SAH (S-Adenosylhomocysteine)		Nucleosides and their Analogs
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

heterodimers

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products